DXCM
Dexcom Inc (DXCM)
Healthcare • NASDAQ • $60.61-0.49%
- Symbol
- DXCM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $60.61
- Daily Change
- -0.49%
- Market Cap
- $23.39B
- Trailing P/E
- 26.01
- Forward P/E
- 19.85
- 52W High
- $89.98
- 52W Low
- $54.11
- Analyst Target
- $83.54
- Dividend Yield
- N/A
- Beta
- 1.40
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Company websiteResearch DXCM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.